Baird Financial Group, Inc. Fate Therapeutics Inc Transaction History

Baird Financial Group, Inc.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 08, 2022	SELL	$17.78 - $42.39 $103,141 - $245,904	-5,801 Closed	0 $0
Q1 2022 May 13, 2022	BUY	$29.67 - $60.28 $56,135 - $114,049	1,892 Added 48.4%	5,801 $225,000
Q3 2021 Nov 12, 2021	BUY	$59.27 - $95.73 $231,686 - $374,208	3,909 New	3,909 $232,000

175

115M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $260M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Baird Financial Group, Inc., based on Form 13F filings with the SEC.

Stay updated on Baird Financial Group, Inc. with notifications on news.